nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—ABCB1—Topotecan—cervical cancer	0.266	1	CbGbCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—PIAS3—cervical cancer	0.0446	0.236	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—WNT2—cervical cancer	0.0287	0.152	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—WNT5A—cervical cancer	0.0218	0.115	CbGpPWpGaD
Lenalidomide—CDH5—epithelium—cervical cancer	0.0196	0.0629	CbGeAlD
Lenalidomide—CDH5—uterine cervix—cervical cancer	0.0194	0.0624	CbGeAlD
Lenalidomide—CDH5—decidua—cervical cancer	0.0185	0.0594	CbGeAlD
Lenalidomide—CDH5—endometrium—cervical cancer	0.0175	0.0564	CbGeAlD
Lenalidomide—CDH5—mammalian vulva—cervical cancer	0.017	0.0546	CbGeAlD
Lenalidomide—CDH5—uterus—cervical cancer	0.0162	0.052	CbGeAlD
Lenalidomide—Acute leukaemia—Topotecan—cervical cancer	0.0151	0.0646	CcSEcCtD
Lenalidomide—CDH5—female reproductive system—cervical cancer	0.0145	0.0467	CbGeAlD
Lenalidomide—CDH5—female gonad—cervical cancer	0.0132	0.0425	CbGeAlD
Lenalidomide—CDH5—vagina—cervical cancer	0.0131	0.0423	CbGeAlD
Lenalidomide—CRBN—uterine cervix—cervical cancer	0.0123	0.0396	CbGeAlD
Lenalidomide—CRBN—decidua—cervical cancer	0.0117	0.0377	CbGeAlD
Lenalidomide—CRBN—renal system—cervical cancer	0.0115	0.0371	CbGeAlD
Lenalidomide—TNFSF11—lymph node—cervical cancer	0.0113	0.0363	CbGeAlD
Lenalidomide—CRBN—endometrium—cervical cancer	0.0111	0.0358	CbGeAlD
Lenalidomide—CRBN—mammalian vulva—cervical cancer	0.0108	0.0347	CbGeAlD
Lenalidomide—CRBN—uterus—cervical cancer	0.0103	0.033	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—NOTCH1—cervical cancer	0.00945	0.05	CbGpPWpGaD
Lenalidomide—CRBN—female reproductive system—cervical cancer	0.00923	0.0297	CbGeAlD
Lenalidomide—Myelosuppression—Topotecan—cervical cancer	0.0092	0.0393	CcSEcCtD
Lenalidomide—CDH5—lymph node—cervical cancer	0.0085	0.0273	CbGeAlD
Lenalidomide—CRBN—female gonad—cervical cancer	0.0084	0.027	CbGeAlD
Lenalidomide—CRBN—vagina—cervical cancer	0.00835	0.0268	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—MTOR—cervical cancer	0.00826	0.0437	CbGpPWpGaD
Lenalidomide—Mucosal inflammation—Topotecan—cervical cancer	0.00779	0.0333	CcSEcCtD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—CTNNB1—cervical cancer	0.00732	0.0387	CbGpPWpGaD
Lenalidomide—Febrile neutropenia—Topotecan—cervical cancer	0.00717	0.0307	CcSEcCtD
Lenalidomide—Pelvic pain—Topotecan—cervical cancer	0.00709	0.0303	CcSEcCtD
Lenalidomide—CDH5—Adherens junctions interactions—CTNNB1—cervical cancer	0.00693	0.0366	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—MTOR—cervical cancer	0.00635	0.0336	CbGpPWpGaD
Lenalidomide—Interstitial lung disease—Topotecan—cervical cancer	0.0061	0.0261	CcSEcCtD
Lenalidomide—Rash erythematous—Topotecan—cervical cancer	0.00563	0.0241	CcSEcCtD
Lenalidomide—Pleural effusion—Topotecan—cervical cancer	0.00563	0.0241	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—STAT3—cervical cancer	0.00557	0.0294	CbGpPWpGaD
Lenalidomide—CRBN—lymph node—cervical cancer	0.0054	0.0174	CbGeAlD
Lenalidomide—Rigors—Topotecan—cervical cancer	0.00529	0.0226	CcSEcCtD
Lenalidomide—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00475	0.0203	CcSEcCtD
Lenalidomide—Blood bilirubin increased—Topotecan—cervical cancer	0.00456	0.0195	CcSEcCtD
Lenalidomide—Bone pain—Topotecan—cervical cancer	0.0045	0.0193	CcSEcCtD
Lenalidomide—Respiratory failure—Topotecan—cervical cancer	0.00439	0.0188	CcSEcCtD
Lenalidomide—Pulmonary embolism—Topotecan—cervical cancer	0.00432	0.0184	CcSEcCtD
Lenalidomide—Colitis—Topotecan—cervical cancer	0.00414	0.0177	CcSEcCtD
Lenalidomide—Neuropathy—Topotecan—cervical cancer	0.00405	0.0173	CcSEcCtD
Lenalidomide—CDH5—Cell-cell junction organization—CTNNB1—cervical cancer	0.00398	0.021	CbGpPWpGaD
Lenalidomide—Neoplasm—Topotecan—cervical cancer	0.0039	0.0167	CcSEcCtD
Lenalidomide—Sepsis—Topotecan—cervical cancer	0.00374	0.016	CcSEcCtD
Lenalidomide—Ear pain—Topotecan—cervical cancer	0.00367	0.0157	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—cervical cancer	0.0036	0.019	CbGpPWpGaD
Lenalidomide—PTGS2—epithelium—cervical cancer	0.00338	0.0109	CbGeAlD
Lenalidomide—PTGS2—uterine cervix—cervical cancer	0.00336	0.0108	CbGeAlD
Lenalidomide—Lethargy—Topotecan—cervical cancer	0.0032	0.0137	CcSEcCtD
Lenalidomide—PTGS2—renal system—cervical cancer	0.00314	0.0101	CbGeAlD
Lenalidomide—PTGS2—endometrium—cervical cancer	0.00304	0.00976	CbGeAlD
Lenalidomide—CDH5—Cell junction organization—CTNNB1—cervical cancer	0.00301	0.0159	CbGpPWpGaD
Lenalidomide—Cardiac arrest—Topotecan—cervical cancer	0.00298	0.0127	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—PIAS3—cervical cancer	0.00287	0.0152	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—MTOR—cervical cancer	0.00283	0.0149	CbGpPWpGaD
Lenalidomide—Cramp muscle—Topotecan—cervical cancer	0.00282	0.0121	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00282	0.0121	CcSEcCtD
Lenalidomide—PTGS2—uterus—cervical cancer	0.0028	0.00899	CbGeAlD
Lenalidomide—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00276	0.0118	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—MTOR—cervical cancer	0.00267	0.0141	CbGpPWpGaD
Lenalidomide—Pancytopenia—Topotecan—cervical cancer	0.00257	0.011	CcSEcCtD
Lenalidomide—Neutropenia—Topotecan—cervical cancer	0.00253	0.0108	CcSEcCtD
Lenalidomide—PTGS2—female reproductive system—cervical cancer	0.00251	0.00808	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	0.00251	0.0132	CbGpPWpGaD
Lenalidomide—Weight increased—Topotecan—cervical cancer	0.00246	0.0105	CcSEcCtD
Lenalidomide—Pneumonia—Topotecan—cervical cancer	0.00243	0.0104	CcSEcCtD
Lenalidomide—Infestation—Topotecan—cervical cancer	0.00241	0.0103	CcSEcCtD
Lenalidomide—Infestation NOS—Topotecan—cervical cancer	0.00241	0.0103	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Topotecan—cervical cancer	0.00237	0.0101	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—CTNNB1—cervical cancer	0.00237	0.0125	CbGpPWpGaD
Lenalidomide—Stomatitis—Topotecan—cervical cancer	0.00235	0.0101	CcSEcCtD
Lenalidomide—Sweating—Topotecan—cervical cancer	0.00231	0.00989	CcSEcCtD
Lenalidomide—PTGS2—female gonad—cervical cancer	0.00229	0.00735	CbGeAlD
Lenalidomide—Hepatobiliary disease—Topotecan—cervical cancer	0.00228	0.00976	CcSEcCtD
Lenalidomide—Epistaxis—Topotecan—cervical cancer	0.00228	0.00973	CcSEcCtD
Lenalidomide—PTGS2—vagina—cervical cancer	0.00227	0.00731	CbGeAlD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.0022	0.0116	CbGpPWpGaD
Lenalidomide—Haemoglobin—Topotecan—cervical cancer	0.00218	0.00931	CcSEcCtD
Lenalidomide—Rhinitis—Topotecan—cervical cancer	0.00217	0.00929	CcSEcCtD
Lenalidomide—Haemorrhage—Topotecan—cervical cancer	0.00217	0.00926	CcSEcCtD
Lenalidomide—Hypoaesthesia—Topotecan—cervical cancer	0.00216	0.00922	CcSEcCtD
Lenalidomide—Pharyngitis—Topotecan—cervical cancer	0.00215	0.00919	CcSEcCtD
Lenalidomide—CDH5—Cell-Cell communication—CTNNB1—cervical cancer	0.00214	0.0113	CbGpPWpGaD
Lenalidomide—ABCB1—epithelium—cervical cancer	0.00209	0.00673	CbGeAlD
Lenalidomide—ABCB1—uterine cervix—cervical cancer	0.00208	0.00667	CbGeAlD
Lenalidomide—ABCB1—decidua—cervical cancer	0.00198	0.00636	CbGeAlD
Lenalidomide—Angiopathy—Topotecan—cervical cancer	0.00197	0.00841	CcSEcCtD
Lenalidomide—Immune system disorder—Topotecan—cervical cancer	0.00196	0.00837	CcSEcCtD
Lenalidomide—Mediastinal disorder—Topotecan—cervical cancer	0.00195	0.00835	CcSEcCtD
Lenalidomide—Chills—Topotecan—cervical cancer	0.00194	0.00831	CcSEcCtD
Lenalidomide—ABCB1—renal system—cervical cancer	0.00194	0.00624	CbGeAlD
Lenalidomide—Alopecia—Topotecan—cervical cancer	0.00191	0.00819	CcSEcCtD
Lenalidomide—Malnutrition—Topotecan—cervical cancer	0.00189	0.00806	CcSEcCtD
Lenalidomide—ABCB1—endometrium—cervical cancer	0.00188	0.00603	CbGeAlD
Lenalidomide—Back pain—Topotecan—cervical cancer	0.00182	0.0078	CcSEcCtD
Lenalidomide—ABCB1—mammalian vulva—cervical cancer	0.00182	0.00584	CbGeAlD
Lenalidomide—Muscle spasms—Topotecan—cervical cancer	0.00181	0.00775	CcSEcCtD
Lenalidomide—Ill-defined disorder—Topotecan—cervical cancer	0.00175	0.00748	CcSEcCtD
Lenalidomide—Anaemia—Topotecan—cervical cancer	0.00174	0.00745	CcSEcCtD
Lenalidomide—ABCB1—uterus—cervical cancer	0.00173	0.00556	CbGeAlD
Lenalidomide—Angioedema—Topotecan—cervical cancer	0.00172	0.00737	CcSEcCtD
Lenalidomide—Malaise—Topotecan—cervical cancer	0.0017	0.00727	CcSEcCtD
Lenalidomide—Leukopenia—Topotecan—cervical cancer	0.00169	0.00722	CcSEcCtD
Lenalidomide—Cough—Topotecan—cervical cancer	0.00165	0.00704	CcSEcCtD
Lenalidomide—Arthralgia—Topotecan—cervical cancer	0.00161	0.00687	CcSEcCtD
Lenalidomide—Myalgia—Topotecan—cervical cancer	0.00161	0.00687	CcSEcCtD
Lenalidomide—Chest pain—Topotecan—cervical cancer	0.00161	0.00687	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00159	0.00682	CcSEcCtD
Lenalidomide—Discomfort—Topotecan—cervical cancer	0.00159	0.00678	CcSEcCtD
Lenalidomide—ABCB1—female reproductive system—cervical cancer	0.00156	0.005	CbGeAlD
Lenalidomide—Infection—Topotecan—cervical cancer	0.00153	0.00654	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.00152	0.00805	CbGpPWpGaD
Lenalidomide—Nervous system disorder—Topotecan—cervical cancer	0.00151	0.00645	CcSEcCtD
Lenalidomide—Thrombocytopenia—Topotecan—cervical cancer	0.00151	0.00644	CcSEcCtD
Lenalidomide—Skin disorder—Topotecan—cervical cancer	0.0015	0.00639	CcSEcCtD
Lenalidomide—Hyperhidrosis—Topotecan—cervical cancer	0.00149	0.00636	CcSEcCtD
Lenalidomide—PTGS2—lymph node—cervical cancer	0.00147	0.00473	CbGeAlD
Lenalidomide—Anorexia—Topotecan—cervical cancer	0.00147	0.00627	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TAAR6—cervical cancer	0.00144	0.00759	CbGpPWpGaD
Lenalidomide—ABCB1—female gonad—cervical cancer	0.00142	0.00455	CbGeAlD
Lenalidomide—ABCB1—vagina—cervical cancer	0.00141	0.00452	CbGeAlD
Lenalidomide—Musculoskeletal discomfort—Topotecan—cervical cancer	0.0014	0.006	CcSEcCtD
Lenalidomide—Paraesthesia—Topotecan—cervical cancer	0.00138	0.00591	CcSEcCtD
Lenalidomide—Dyspnoea—Topotecan—cervical cancer	0.00137	0.00587	CcSEcCtD
Lenalidomide—Dyspepsia—Topotecan—cervical cancer	0.00136	0.00579	CcSEcCtD
Lenalidomide—Decreased appetite—Topotecan—cervical cancer	0.00134	0.00572	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Topotecan—cervical cancer	0.00133	0.00568	CcSEcCtD
Lenalidomide—Fatigue—Topotecan—cervical cancer	0.00133	0.00567	CcSEcCtD
Lenalidomide—Pain—Topotecan—cervical cancer	0.00132	0.00563	CcSEcCtD
Lenalidomide—Constipation—Topotecan—cervical cancer	0.00132	0.00563	CcSEcCtD
Lenalidomide—Feeling abnormal—Topotecan—cervical cancer	0.00127	0.00542	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Topotecan—cervical cancer	0.00126	0.00538	CcSEcCtD
Lenalidomide—Urticaria—Topotecan—cervical cancer	0.00122	0.00523	CcSEcCtD
Lenalidomide—Abdominal pain—Topotecan—cervical cancer	0.00122	0.0052	CcSEcCtD
Lenalidomide—Body temperature increased—Topotecan—cervical cancer	0.00122	0.0052	CcSEcCtD
Lenalidomide—Hypersensitivity—Topotecan—cervical cancer	0.00113	0.00485	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—WNT2—cervical cancer	0.00112	0.00592	CbGpPWpGaD
Lenalidomide—Asthenia—Topotecan—cervical cancer	0.0011	0.00472	CcSEcCtD
Lenalidomide—Pruritus—Topotecan—cervical cancer	0.00109	0.00466	CcSEcCtD
Lenalidomide—Diarrhoea—Topotecan—cervical cancer	0.00105	0.0045	CcSEcCtD
Lenalidomide—Dizziness—Topotecan—cervical cancer	0.00102	0.00435	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—AKAP13—cervical cancer	0.000984	0.0052	CbGpPWpGaD
Lenalidomide—Vomiting—Topotecan—cervical cancer	0.000979	0.00418	CcSEcCtD
Lenalidomide—Rash—Topotecan—cervical cancer	0.000971	0.00415	CcSEcCtD
Lenalidomide—Dermatitis—Topotecan—cervical cancer	0.00097	0.00415	CcSEcCtD
Lenalidomide—Headache—Topotecan—cervical cancer	0.000964	0.00412	CcSEcCtD
Lenalidomide—Nausea—Topotecan—cervical cancer	0.000914	0.00391	CcSEcCtD
Lenalidomide—ABCB1—lymph node—cervical cancer	0.00091	0.00292	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—WNT5A—cervical cancer	0.000849	0.00449	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000821	0.00434	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HES1—cervical cancer	0.000818	0.00432	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000781	0.00413	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000699	0.00369	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—cervical cancer	0.000693	0.00366	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—cervical cancer	0.000645	0.00341	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.000641	0.00339	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000616	0.00326	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH2—cervical cancer	0.000596	0.00315	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000553	0.00292	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—cervical cancer	0.00055	0.00291	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000526	0.00278	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HES1—cervical cancer	0.000489	0.00258	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—cervical cancer	0.000462	0.00244	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TERT—cervical cancer	0.000428	0.00226	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP8—cervical cancer	0.000419	0.00221	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGFR3—cervical cancer	0.000393	0.00208	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH1—cervical cancer	0.000369	0.00195	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—cervical cancer	0.000324	0.00171	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—cervical cancer	0.000317	0.00167	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000292	0.00154	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MTOR—cervical cancer	0.000277	0.00146	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP3—cervical cancer	0.000254	0.00134	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—cervical cancer	0.000248	0.00131	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—cervical cancer	0.000245	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000221	0.00117	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WNT2—cervical cancer	0.000216	0.00114	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—cervical cancer	0.000214	0.00113	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000213	0.00112	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—cervical cancer	0.000208	0.0011	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000207	0.00109	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—cervical cancer	0.000194	0.00103	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CA9—cervical cancer	0.000171	0.000902	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000168	0.00089	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WNT5A—cervical cancer	0.000164	0.000865	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—cervical cancer	0.000163	0.000862	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000156	0.000827	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000151	0.000797	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000141	0.000748	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA9—cervical cancer	0.000121	0.00064	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000119	0.000631	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.0001	0.00053	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HES1—cervical cancer	9.42e-05	0.000498	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—cervical cancer	8.27e-05	0.000437	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—cervical cancer	8.25e-05	0.000436	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR3—cervical cancer	7.57e-05	0.0004	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOTCH1—cervical cancer	7.11e-05	0.000376	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—cervical cancer	6.93e-05	0.000366	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTOR—cervical cancer	5.33e-05	0.000282	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—cervical cancer	5.32e-05	0.000281	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—cervical cancer	4.91e-05	0.00026	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—cervical cancer	4.72e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—cervical cancer	4.12e-05	0.000218	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—cervical cancer	3.74e-05	0.000198	CbGpPWpGaD
